Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: A concise review

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 3, 2011, Pages 331-346

  Marchesi, Francesco ^a   Annibali, Ombretta ^a   Cerchiara, Elisabetta ^a   Tirindelli, Maria Cristina ^a   Avvisati, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Acute myeloid leukemia; Cytogenetic abnormalities; Cytogenetic risk; Prognostic stratification

Indexed keywords

LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; CARCINOGENESIS; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DELETION 5; CHROMOSOME DELETION 7; CHROMOSOME INVERSION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 10; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 3; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 8; CHROMOSOME TRANSLOCATION 9; CLINICAL CLASSIFICATION; DOWN SYNDROME; DRUG EFFICACY; DRUG MEGADOSE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; KARYOTYPING; MONOSOMY; PROGNOSIS; REVIEW; RISK ASSESSMENT; TETRASOMY; TRISOMY 13; TRISOMY 8;

ADULT; CHROMOSOME ABERRATIONS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; RISK ASSESSMENT;

EID: 80655125052     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.11.006     Document Type: Review

References (101)

1. Mrózek K., Heinonen K., Bloomfield C.D. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001, 14:19-47.
2. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patient entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
3. Byrd J.C., Mrózek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
4. Slovak M.L., Kopecy K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
5. Mrózek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute myeloid leukemia. Blood Rev 2004, 18:115-136.
6. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
7. Morra E., Barosi G., Bosi A., et al. Clinical management of primary non-acute promyelocytic acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2009, 94:102-112.
8. Cheson B.D., Bennett J.M., Kopecy K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
9. Marcucci G., Mrózek K., Ruppert A.S., et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. J Clin Oncol 2004, 22:2410-2418.
10. Blum W. Post-remission therapy in acute myeloid leukemia: what should I do now? Haematologica 2008, 93:801-804.
11. Mrózek K., Bloomfield C. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2006, 169-177.
12. Farag S.S., Archer K.J., Mrózek K., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: result from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
13. Mrózek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
14. Marcucci G., Mrózek K., Ruppert A.S., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23:5705-5717.
15. Mrózek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008, 35:365-377.
16. De Botton S., Chevret S., Sanz M., et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL93 trial. Br J Haematol 2000, 111:801-806.
17. Schlenk R.F., Benner A., Krauter J., et al. Individual patients data-base meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004, 22:3741-3750.
18. Fröhling S., Schlenk R.F., Kayser S., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patient older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108:3280-3288.
19. Rücker F.G., Bullinger L., Schwaenen C., et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006, 24:3887-3894.
20. Schoch C., Haferlach T., Haase D., et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001, 112:118-126.
21. Schoch C., Kern W., Kohlmann A., Hiddemann W., Schnittger S., Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005, 43:227-238.
22. Van Limbergen H., Poppe B., Michaux L., et al. Identification of cytogenetic subclasses and recurring chromosomal aberrations ain AML and MDS with complex karyotype using M-FISH. Genes Chromosomes Cancer 2002, 33:60-72.
23. Stark B., Jeison M., Gabay L.G., et al. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from referral centre in Israel. Br J Haematol 2004, 126:320-327.
24. Betts D.R., Ammann R.A., Hirt A., et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol 2007, 78:468-476.
25. Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduce-intensity conditioning for allogenic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodisplatic syndrome. J Clin Oncol 2005, 23:5675-5687.
26. Tallman M.S., Dewald G.W., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007, 110:409-417.
27. Blum W., Klisovic R.B., Hackanson B., et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007, 25:3884-3891.
28. Lahortiga I., Vázquez I., Agirre X., et al. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Gene Chromosomes Cancer 2004, 40:179-189.
29. Levy E.R., Parganas E., Morishita K., et al. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. Blood 1994, 83:1348-1354.
30. Suzukawa K., Parganas E., Gajjar A., et al. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the trascriptional activation of the EVI1 gene in acute myelogenous leukemia with inv(3)(q21q26). Blood 1994, 84:2681-2688.
31. Testa U., Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007, 92:81-94.
32. Secker-Walker L.M., Mehta A., Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995, 91:490-501.
33. Testoni N., Borsaru G., Martinelli G., et al. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. Haematologica 1999, 84:690-694.
34. Chi Y., Lindgren V., Quigley S., Gaitonde S. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med 2008, 132:1835-1837.
35. Garçon L., Libura M., Delabesse E., et al. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 2005, 19:1338-1344.
36. Slovak M.L., Gundacker H., Bloomfield C.D., et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasized the need for a prospective, multicenter initiative for rare "poor prognosis" myeloid malignancies. Leukemia 2006, 20:1295-1297.
37. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
38. Oyarzo M.P., Lin P., Glassman A., Bueso-Ramos C.E., Luthra R., Medeiros L.J. Acute myelogenous leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of FLT3 gene mutations. Am J Clin Pathol 2004, 122:348-358.
39. Alsabeh R., Brynes R.K., Slovak M.L., Arber D.A. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol 1997, 107:430-437.
40. Gervais C., Murati A., Helias C., et al. Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia 2008, 22:1567-1575.
41. Borrow J., Stanton V.P., Andresen J.M., et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996, 14:33-41.
42. Chaffanet M., Gressin L., Preudhomme C., Soenen-Cornu V., Birnbaum D., Pébusque M.J. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 2000, 28:138-144.
43. Esteyries S., Perot C., Adelaide J., et al. NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia 2008, 22:663-665.
44. Velloso E.R., Mecucci C., Michaux L., et al. Translocation t(8;16)(p11;p13) in acute non-lymphocitic leukemia: report of wo cases and review of the literature. Leuk Lymph 1996, 21:137-142.
45. Sun T., Wu E. Acute monoblastic leukemia with t(8;16): a distinct clinicopathologic entity; report of a case and review of the literature. Am J Hematol 2001, 66:207-212.
46. Coulthard S., Chase A., Orchard K., et al. Two cases of inv(8)(p11q13) in AML with erytrophagocytosis: a new cytogenetic variant. Br J Haematol 1998, 100:561-563.
47. Panagopoulos I., Teixeira M.R., Micci F., et al. Acute myeloid leukemia with inv(8)(p11q13). Leuk Lymphoma 2000, 39:651-656.
48. Carapeti M., Aguiar R.C., Goldman J.M., Cross N.C. A novel fusion between MOZ and the nuclear receptor coafactor TIF2 in acute myeloid leukemia. Blood 1998, 91:3127-3133.
49. Arber D.A., Chang K.L., Lyda M.H., Bedell V., Spielberger R., Slovak M.L. Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. Human Pathol 2003, 34:809-813.
50. Xie J., Briggs J.A., Morris S.W., Olson M.O., Kinney M.C., Briggs R.C. MNDA binds NPM/B23 and the NPM/MLF1 chimera generated by t(3;5) associated with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol 1997, 25:1111-1117.
51. Bloomfield C.D., Archer K.J., Mrózek K., et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002, 33:362-378.
52. Cox M.C., Panetta P., Lo-Coco F., et al. Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene trans location: results in 378 adult patients. Am J Pathol 2004, 122:298-306.
53. Tamai H., Yamaguchi H., Hamaguchi H., et al. Clinical features of adult myeloid leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. Int J Hematol 2008, 87:195-202.
54. Zhang Y., Rowley J.D. Chromatin structural elements and chromosomal translocation in leukemia. DNA Repair 2006, 5:1282-1297.
55. Ayton P.M., Cleary M.L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001, 20:5695-5707.
56. Krauter J., Wagner K., Schäfer I., et al. Prognostic factors in adult patients up of 60 years with acute myeloid leukemia and translocations of chromosome band 11q23: individual patients data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2009, 27:3000-3006.
57. Strout M.P., Marcucci G., Caligiuri M.A., Bloomfield C.D. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol 1999, 78:251-264.
58. Vendrame-Goloni C.B., Varella-Garcia M., Carvalho-Salles A.B., Ruiz M.A., Júnior O.R., Fett-Conte A.C. Translocation (11;19)(q23;p13.3) associated with a novel t(5;16)(q12;q22) in a patient with acute myelocytic leukemia. Cancer Gen Cytogen 2003, 141:71-74.
59. Daser A., Rabbitts T.H. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 2004, 18:965-974.
60. Caudell D., Aplan P.D. The role of CALM-AF10 gene fusion in acute leukemia. Leukemia 2008, 22:678-685.
61. Brozek I., Babińska M., Kardaś I., et al. Cytogenetic analysis and clinical significance of chromosome 7 aberrations in acute leukaemia. J Appl Genet 2003, 44:401-412.
62. Hasle H., Aricò M., Basso G., et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia with complete or partial monosomy 7. Leukemia 1999, 13:376-385.
63. Breems D., Van Putten W.L.J., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26:4791-4797.
64. Woo K.S., Kim K.E., Kim K.H., et al. Deletions of chromosome arms 7p and 7q in adult acute myeloid leukemia: a marker chromosome confirmed by array comparative genomic hybridization. Cancer Gen Cytogen 2009, 194:71-74.
65. Cigognini D., Corneo G., Fermo E., Zanella A., Tripputi P. HIC gene, a candidate suppressor gene with a minimal region of loss at 7q31.1 in myeloid neoplasms. Leuk Res 2007, 31:477-482.
66. Ernst T., Chase A.J., Score J., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42:722-726.
67. Nikoloski G., Langemeijer S.M., Kuiper R.P., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010, 42:665-667.
68. Lessard M., Hélias C., Struski S., et al. Fluorescence in situ hybridization of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome - acute myeloid leukemia actually differ?. Cancer Gen Cytogen 2007, 176:1-21.
69. Baldus C.D., Mrózek K., Marcucci G., Bloomfield C.D. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br J Haematol 2007, 137:387-400.
70. Döhner H. Implication of the molecular characterization of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007, 412-419.
71. Atlas M., Head D., Behm F., et al. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia 1998, 12:1895-1902.
72. Langer T., Metzler M., Reinhardt D., et al. Analysis of t(9;11) chromosomal breakpoints sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer 2003, 36:393-401.
73. Paulsson K., Johansson B. Trisomy 8 as sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathol Biol 2007, 55:37-48.
74. Paulsson K., Säll T., Fioretos T., Mitelman F., Johansson B. The incidence of trisomy 8 as sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Gen Cytogen 2001, 130:160-165.
75. De Souza Fernandez T., Silva M.L., De Souza J., De Paula M.T., Abdelhay E. C-MYC amplification in a case of progression from MDS to AML (M2). Cancer Gen Cytogen 1996, 86:183-184.
76. Mertens F., Johansson M., Mitelman F. The pathogenetic significance of acquired trisomy 8 is not reducible to amplification of a single chromosome band. Cancer Gen Cytogen 1995, 83:176-177.
77. Wolstenholme J. Confined placental mosaicism for trisomies 2, 3, 7, 8, 9, 16, and 22: their incidence, likely origins, and mechanisms for cell lineage compartmentalization. Prenat Diagn 1996, 16:511-524.
78. Welbern J. Constitutional chromosome aberrations as pathogenetic event in hematologic malignancies. Cancer Gen Cytogen 2004, 149:137-153.
79. Schaich M., Schlenk R.F., Al-Ali H.K., et al. Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica 2007, 92:763-770.
80. Yan J., Marceau D., Drouin R. Tetrasomy 8 is associated with a major cellular proliferative advantage and a poor prognosis: two cases of myeloid hematologic disorders and review of the literature. Cancer Gen Cytogen 2001, 125:14-20.
81. Heinonen K., Mrózek K., Lawrence D., et al. Clinical characteristics of patients with de novo acute myeloid leukemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol 1998, 101:513-520.
82. Sierra M., Hernández J.M., García J.L., et al. Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11. Cancer Gen Cytogen 2005, 160:68-72.
83. Rege-Cambrin G., Giugliano E., Michaux L., et al. Trisomy 11 in myeloid malignancies is associated with internal tandem duplication of both MLL and FLT3 genes. Haematologica 2005, 90:262-264.
84. Jamal R., Taketani T., Taki T., et al. Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. Genes Chromosomes Cancer 2001, 31:187-190.
85. Silva F.P., Lind A., Brouwer-Mandema G., Valk P.J., Giphart-Gassler M. Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica 2007, 92:1123-1126.
86. Dicker F., Haferlach C., Kern W., Haferlach T., Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007, 110:1308-1316.
87. Fehniger T.A., Byrd J.C., Marcucci G., et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009, 113:1002-1005.
88. Malinge S., Izraeli S., Crispino J.D. Insights into the manifestations, outcomes, and mechanism of leukemogenesis in Down syndrome. Blood 2009, 113:2619-2628.
89. Rao A., Hills R.K., Stiller C., et al. Treatment for myeloid leukemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006, 132:576-583.
90. Speck N.A. Core binding factor and its role in normal hematopoietic development. Curr Opin Hematol 2001, 8:192-196.
91. Downing J.R. The core binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev 2003, 13:48-54.
92. Kita K., Nakase K., Miwa H., et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992, 80:470-477.
93. Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58:4173-4179.
94. Byrd J.C., Dodge R.K., Carroll A., et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999, 17:3767-3775.
95. Schlenk R.F., Benner A., Hartmann F., et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 2003, 17:1521-1528.
96. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol 2006, 24:3904-3911.
97. Mrózek K., Heinonen K., de la Chapelle A., Bloomfield C.D. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997, 24:17-31.
98. Delaunay J., Vey N., Leblanc T., et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003, 102:462-469.
99. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
100. Maurillo L., Buccisano F., Del Principe M.I., et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008, 26:4944-4951.
101. Lo-Coco F., Cuneo A., Pane F., et al. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study foe newly diagnosed acute myeloid leukemia. Haematologica 2008, 93:1017-1024.